Trial Profile
Treatment of Solid Tumors With Intratumoral Hiltonol (Poly-ICLC): A Phase II Clinical Study
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Poly ICLC (Primary)
- Indications Basal cell cancer; Breast cancer; Head and neck cancer; Malignant melanoma; Skin cancer; Squamous cell cancer
- Focus Therapeutic Use
- 07 Jun 2016 Results presented at the 52nd Annual Meeting of the American Society of Clinical Oncology.
- 27 Oct 2014 According to the ClinicalTrials.gov record, status changed from active, no longer recruiting to discontinued.
- 03 Jun 2014 The study design published as abstract in Journal of Clinical Oncology in conjunction with the 2014 ASCO Annual Meeting.